Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2026 07:00 ET | Source: Kyntra Bio

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16...
February 23, 2026 17:10 ET | Source: Kyntra Bio

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer...
February 17, 2026 16:05 ET | Source: Kyntra Bio

Kyntra Bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company’s management will participate in the following investor...
January 07, 2026 07:30 ET | Source: FibroGen, Inc.

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq...
December 15, 2025 07:00 ET | Source: FibroGen, Inc.

Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration

Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of...
December 02, 2025 16:05 ET | Source: FibroGen, Inc.

FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit...
November 10, 2025 16:02 ET | Source: FibroGen, Inc.

FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update

Completed the sale of FibroGen China to AstraZeneca for approximately $220 millionInitiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting...
November 03, 2025 16:02 ET | Source: FibroGen, Inc.

FibroGen to Report Third Quarter 2025 Financial Results

SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also...
September 24, 2025 07:00 ET | Source: FibroGen, Inc.

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy...
September 02, 2025 07:00 ET | Source: FibroGen, Inc.

FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million

Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidanceSuccessfully repaid term loan to Morgan Stanley Tactical...